Tag: clinical trial

TL;DR

• Retatrutide, Eli Lilly’s triple‑agonist (GLP‑1/GIP/glucagon), produced an average 25% weight loss at week 80 at the 12 mg dose in TRIUMPH‑1 (n=2,339), with a two‑year extension approaching ~30%; knee osteoarthritis pain and obstructive sleep apnea events also improved versus placebo [1].
• Lilly is positioning retatrutide alongside Zepbound rather than against it, using outcomes that matter to payers—obstructive sleep apnea (FDA‑approved for Zepbound in 2024) and cardiovascular risk (FDA‑approved for Wegovy in 2024)—to expand coverage beyond “weight loss only” claims [4][5].
• Goldman Sachs models ~$95B in global anti‑obesity drug sales by 2030; even a 10% slice would be multibillion revenue, contingent on Lilly’s $3.5B Pennsylvania manufacturing build and payer adoption following outcomes labels recognized by Medicare Part D [6][8][7].

What the source said

Lilly reported that, in TRIUMPH‑1, adults with obesity but without diabetes receiving weekly retatrutide 12 mg lost a mean 25% of baseline body weight by week 80 (phase 3; n=2,339), with gastrointestinal events common and ~11% discontinuations due to adverse events [1]. Among participants with knee osteoarthritis (n≈574), pain scores declined more than on placebo; in obstructive sleep apnea (n≈243), the apnea‑hypopnea index fell by more than 30 events per hour on retatrutide versus roughly 10 per hour on placebo, suggesting clinically meaningful improvement [1]. A two‑year extension cohort neared an average ~30% loss, although no head‑to‑head trial versus semaglutide or tirzepatide was conducted in this program [1].

Why it matters

• U.S. payers—including Medicare Part D plans, state Medicaid programs, and self‑insured employers—tend to reimburse labeled outcomes they already manage, such as cardiovascular risk and obstructive sleep apnea; Wegovy’s 2024 FDA cardiovascular‑risk label enabled Part D coverage pathways, which retatrutide could emulate if it secures outcomes‑based indications [4][7].
• Supply will gate share just as much as efficacy; Lilly’s announced $3.5B injectable/device facility in Lebanon County, Pennsylvania adds capacity on top of prior sites to reduce shortages that limited first‑wave GLP‑1 uptake in 2023–2024 [8].

Original analysis

Efficacy stack‑up (cross‑trial optics, not equivalence)

• Retatrutide 12 mg: −25.0% at 80 weeks in TRIUMPH‑1; two‑year extension near ~30% in a subset [1].
• Tirzepatide 15 mg (SURMOUNT‑1): −22.5% at 72 weeks in adults with obesity [3].
• Semaglutide 2.4 mg (STEP 1): −14.9% at 68 weeks in adults with obesity/overweight [2].

Cross‑trial comparisons are imperfect, but the ordering is consistent: retatrutide > tirzepatide > semaglutide on average percentage loss at peak doses and similar durations [1][2][3]. TRIUMPH‑1’s added endpoints—apnea‑hypopnea index reduction and knee pain improvement—map to reimbursed services like sleep studies, PAP supplies, and orthopedic visits, which strengthens the coverage case beyond pounds lost [1].

— Back‑of‑envelope: revenue sizing with shown work
Goldman Sachs pegs 2030 anti‑obesity drug sales near $95B globally [6]. If Lilly holds 45% obesity share across its franchise by 2030 and retatrutide drives 25% of Lilly’s obesity revenue, implied annual sales are $95B × 0.45 × 0.25 = $10.69B (≈$10.7B) [6]. This scenario assumes Zepbound remains the volume leader while retatrutide captures the premium‑efficacy/outcomes tier.

— 2×2: “Efficacy × Coverage” positioning

• High efficacy / Broad coverage: Targets outcomes‑labeled indications (e.g., OSA, CV risk) that Medicare Part D and commercial plans already cover; Zepbound holds an FDA OSA label from 2024, and Wegovy holds a 2024 CV‑risk label, establishing the playbook [5][4].
• High efficacy / Narrow coverage: Likely starting point for retatrutide at launch if weight loss dominates the label without immediate outcomes endpoints [1].
• Moderate efficacy / Broad coverage: Semaglutide’s CV‑risk label extends access to eligible Part D beneficiaries regardless of diabetes status [4].
• Moderate efficacy / Narrow coverage: Where earlier‑stage competitors sit until they translate weight loss into claim‑linked outcomes and codes.

— Contrarian read
Consensus says “25–30% weight loss wins by itself,” but 2024–2026 payer behavior shows labels drive budgets: Wegovy scaled Part D access with its CV‑risk indication, and Zepbound unlocked an OSA path via FDA approval in 2024 [4][5]. Retatrutide’s outcomes signals look strong, yet broad reimbursement will hinge on the exact language that lands on the U.S. label and how quickly those endpoints are reflected in coverage policies [1][7]. Expect Lilly to prioritize outcomes submissions to convert trial endpoints into billable, code‑aligned reasons to pay.

— Named‑stakeholder breakdown

• Eli Lilly and Company: Portfolio management is key; Lilly can segment Zepbound for volume and retatrutide for peak efficacy/outcomes while de‑risking supply through the $3.5B Pennsylvania site announced in 2024 [8].
• Novo Nordisk: Wegovy’s 2024 FDA cardiovascular indication widened Medicare Part D doors, shaping price anchors and coverage precedents that any newcomer, including retatrutide, must meet or exceed [4].
• Medicare Part D plans: CMS signaled in 2024 that FDA‑approved CV‑risk reduction with semaglutide is coverable under Part D, setting a template for outcomes‑labeled anti‑obesity medicines and influencing employer and Medicaid policies in 2025–2027 [7][4].

What others are missing

The pivotal angle is label architecture tied to billable outcomes, not another 2–5 percentage points of weight loss; Medicare’s 2024 acceptance of Wegovy’s CV‑risk indication for Part D, plus Zepbound’s 2024 OSA approval, show that coverage flows to conditions with existing codes and utilization management playbooks (AHI thresholds, CPAP claims, CV events) [4][5]. Retatrutide’s trial endpoints mirror those realities—apnea‑hypopnea reductions and osteoarthritis pain scores—so the gating item is whether Lilly wins explicit outcomes language on the U.S. label in time to influence 2027 benefit designs and formularies [1][7].

What to watch next

1. By December 31, 2027, Lilly submits a U.S. application for retatrutide in obesity with at least one outcomes endpoint (OSA or OA) included in the filing package.
2. By June 30, 2028, Lilly’s Lebanon County, Pennsylvania site reaches commercial production of GLP‑1/GIP/glucagon‑class injectables to support retatrutide or Zepbound scale‑up [8].
3. By September 30, 2028, at least two top‑10 Medicare Part D plans publish coverage criteria that explicitly reference outcomes labels (OSA or CV risk) as primary gateways for anti‑obesity drug access [7][4][5].

My take

Retatrutide has reset the efficacy ceiling to roughly 25–30% average loss over 80–104 weeks in non‑diabetic adults, which is a clinical leap but not a coverage guarantee in the United States [1]. The next competitive phase favors drugs that combine high efficacy with outcomes‑based labels that plans already know how to reimburse, plus dependable supply chains that avoid the 2023–2024 shortages. Lilly looks positioned to run that playbook: Zepbound carries an OSA label from 2024, Wegovy has a CV‑risk precedent to match, and the Pennsylvania capacity expansion supports scale. The likely 2027–2029 strategy is portfolio lock‑in: Zepbound for broad, outcomes‑anchored access and retatrutide as the premium, outcomes‑rich sequel.

Sources

1. Eli Lilly — TRIUMPH‑1 retatrutide topline (Phase 3) and key endpoints (https://investor.lilly.com/news-releases) — Primary efficacy figures (−25% at 80 weeks), discontinuations, and OA/OSA endpoint summaries used for the trial facts.

2. New England Journal of Medicine — STEP 1: Once‑Weekly Semaglutide 2.4 mg in Adults with Overweight or Obesity (https://www.nejm.org/doi/full/10.1056/NEJMoa2032183) — Benchmark −14.9% at 68 weeks to contextualize legacy GLP‑1 efficacy.

3. New England Journal of Medicine — SURMOUNT‑1: Tirzepatide in Obesity (https://www.nejm.org/doi/full/10.1056/NEJMoa2206038) — Benchmark −22.5% at 72 weeks for tirzepatide to anchor cross‑trial optics.

4. U.S. Food and Drug Administration — Wegovy cardiovascular‑risk reduction approval (2024) (https://www.fda.gov/news-events/press-announcements/) — Confirms a CV‑risk indication that Part D plans can and do cover.

5. U.S. Food and Drug Administration — Zepbound obstructive sleep apnea approval (2024) (https://www.fda.gov/news-events/press-announcements/) — Establishes the first FDA‑approved medication for OSA in adults with obesity, a key outcomes precedent.

6. Goldman Sachs — Anti‑obesity market outlook (~$95B by 2030) (https://www.goldmansachs.com/insights/) — Market sizing and price‑erosion context for the back‑of‑envelope revenue scenario.

7. Centers for Medicare & Medicaid Services — Medicare Part D coverage communications for obesity drugs with outcomes labels (2024) (https://www.cms.gov/newsroom) — Clarifies how FDA‑labeled CV‑risk indications expand Part D coverage pathways.

8. Eli Lilly — $3.5B Pennsylvania manufacturing site announcement (2024) (https://investor.lilly.com/news-releases) — Details on Lebanon County capacity build relevant to supply and launch readiness.

A surprising pivot from Insmed: what the BiRCh results mean for brensocatib and the company’s strategy

The biotech world loves dramatic arcs: a promising molecule rises, investors cheer, and then — sometimes — the plot takes an unexpected turn. On December 17, 2025, Insmed released topline results from the Phase 2b BiRCh study of brensocatib in chronic rhinosinusitis without nasal polyps (CRSsNP). The verdict was blunt: the study did not meet its primary or secondary efficacy endpoints. Insmed immediately discontinued the CRSsNP program, while also announcing the acquisition of a Phase 2-ready monoclonal antibody, INS1148, to bolster its respiratory and inflammatory pipeline.

Let’s unpack what happened, why it matters, and where Insmed might reasonably go from here.

Quick summary of the news

• Date of announcement: December 17, 2025.
• Study: Phase 2b BiRCh — brensocatib versus placebo in CRSsNP, 24 weeks, ~288 patients across 104 sites.
• Result: Neither the 10 mg nor 40 mg dose met the primary endpoint (change in sinus Total Symptom Score) or secondary endpoints.
• Safety: No new safety signals; tolerability consistent with prior studies, including in the higher 40 mg arm.
• Immediate corporate action: Insmed discontinued the CRSsNP development program for brensocatib.
• Simultaneous strategic move: Acquisition of INS1148 (OpSCF), a monoclonal antibody intended for interstitial lung disease and moderate-to-severe asthma; Insmed plans Phase 2 development.

Why the BiRCh failure matters

• Brensocatib had momentum. The drug showed promising results in non-cystic fibrosis bronchiectasis (NCFB) and had become a central part of Insmed’s growth story. Expectations built around expanding brensocatib into other inflammatory and respiratory indications.
• CRSsNP is biologically complex with no reliable animal models. Insmed described the BiRCh trial as a proof-of-concept aimed at testing whether brensocatib’s DPP1 inhibition could translate into symptom relief. The neutral result gives a clear — if disappointing — answer.
• Financial and R&D implications. Discontinuing a development program reduces near-term R&D spend on that indication, but it also cuts potential long-term upside if CRSsNP had proven a meaningful market. The market reaction (sharp stock drop reported in related coverage) reflects lost optionality and investor re-pricing of future revenue scenarios.
• Scientific signal. The lack of efficacy despite adequate dosing (including the company’s highest dose tested) raises mechanistic questions about neutrophil serine protease inhibition in CRSsNP specifically. It also tempers optimism for other indications where the drug’s mechanism is less directly validated.

What the data showed (topline numbers)

• Primary endpoint (28-day average of daily sTSS at Week 24):
  • Placebo LS mean: -2.44
  • Brensocatib 10 mg LS mean: -2.21
  • Brensocatib 40 mg LS mean: -2.33
• Safety: Treatment-emergent adverse events were similar between arms; no new safety concerns, and serious adverse event rates were low and comparable.

Those numbers show minimal separation from placebo on symptom improvement — the clinical signal simply wasn’t there.

The strategic pivot: INS1148 acquisition

• What Insmed bought: INS1148 is a monoclonal antibody (formerly OpSCF) that targets a specific isoform of Stem Cell Factor (SCF248). The proposed advantage is to block the inflammatory cascade downstream of c-Kit signaling while sparing homeostatic/tissue-healing pathways.
• Initial focus: Insmed plans Phase 2 programs in interstitial lung disease and moderate-to-severe asthma. This aligns with the company’s pulmonary focus and offers a new, complementary modality (mAb vs small-molecule DPP1 inhibitor).
• Why this matters: Acquiring a clinical-stage asset diversifies Insmed’s pipeline at a time when brensocatib’s expansion into CRSsNP is off the table. It signals the company is doubling down on respiratory/inflammatory areas while mitigating the impact of the BiRCh result.

The investor dilemma

• Near-term pain: Market volatility is expected after a late-2025 negative readout on an eagerly watched indication. Analysts and short-term traders will re-evaluate revenue forecasts and valuation multiples.
• Longer-term perspective: Insmed still has commercial momentum from brensocatib in bronchiectasis (marketed as Brinsupri in some territories), other ongoing studies (e.g., hidradenitis suppurativa CEDAR study), and now INS1148 to potentially broaden indications. For investors with a multi-year horizon, the company’s runway and portfolio execution matter more than a single failed indication.
• Risk-reward recalibration: The failure reduces optionality and likely moderates peak-sales estimates for brensocatib overall. But the absence of new safety signals and the company’s ability to redeploy capital toward a novel mAb program may keep upside for those who believe in Insmed’s broader strategy.

What this means for brensocatib’s other programs

• Hidradenitis suppurativa (HS) and other non-pulmonary indications may be scrutinized more closely. A lack of efficacy in CRSsNP doesn’t doom those programs, but it raises caution and increases the value of positive, indication-specific data.
• For bronchiectasis, prior strong late-stage results remain intact. Regulatory and commercial timelines for that indication are independent of the CRSsNP result, but market expectations may be tempered.

Takeaways for clinicians, patients, and industry watchers

• Clinicians and patients with CRSsNP: The BiRCh data suggest brensocatib will not become an option for CRSsNP. Patients should continue following evidence-based care and consult their physicians for approved therapies and management strategies.
• Industry watchers: This is a reminder that translating mechanism-based therapies into symptom relief in human disease is hard, especially in diseases lacking translational animal models. Creative acquisitions (like INS1148) are a common industry response to maintain pipeline momentum.

My take

Insmed’s BiRCh outcome is a textbook example of how clinical development reorders expectations. The result is disappointing, but not catastrophic: the company still has a commercially relevant product in bronchiectasis and a pipeline it can re-shape. Acquiring INS1148 is a pragmatic move — it signals an appetite to diversify modality risk and lean into respiratory immunology with a different mechanism.

Failures like this sting publicly because they are visible and immediate. But they can also sharpen corporate focus. If Insmed executes well on ongoing brensocatib programs and advances INS1148 thoughtfully into Phase 2, the company can emerge with a clearer, perhaps stronger strategic identity — albeit one that looks different than the path investors may have anticipated at the start of 2025.

Further reading

• Insmed press release: “Insmed Provides Clinical and Business Update” (December 17, 2025) — for the full topline text and company commentary.
• Reuters and other industry coverage — for market reaction and context around brensocatib’s prior successes in bronchiectasis.

Sources

• Insmed Provides Clinical and Business Update. Insmed Incorporated, December 17, 2025.
  https://investor.insmed.com/2025-12-17-Insmed-Provides-Clinical-and-Business-Update

• Insmed's lung disease drug succeeds in late-stage study. Reuters, May 28, 2024.
  https://www.reuters.com/business/healthcare-pharmaceuticals/insmeds-lung-disease-drug-succeeds-late-stage-study-2024-05-28/

When a Rival’s Win Becomes Your Windfall

Bristol Myers Squibb (BMY) got a bump on Monday — not because of its own press release, but because Bayer released what analysts called a “surprisingly positive” update on its experimental blood thinner, asundexian. The result: investors breathed new life into the broader class of Factor XIa inhibitors and pushed Bristol Myers shares higher. It’s one of those market moments that shows how biotech is often a group sport — your competitor’s breakthrough can validate your pipeline overnight.

Why a Bayer trial moved Bristol Myers

• Bayer’s Phase III OCEANIC‑STROKE trial reported that asundexian (50 mg daily), given with standard antiplatelet therapy, significantly reduced recurrent ischemic stroke risk in patients after a non‑cardioembolic ischemic stroke or high‑risk transient ischemic attack — and crucially, without increasing major bleeding. (bayer.com)
• Factor XIa inhibitors (the drug class) aim to uncouple thrombosis from normal hemostasis — meaning they could prevent clotting events like stroke while lowering bleeding risk compared with existing anticoagulants. That mechanism is precisely what drug developers such as Bristol Myers (milvexian) and others are trying to prove. (bayer.com)
• Investors treat successful late‑stage results for one program as partial proof‑of‑concept for the whole class. Bayer’s win raised the perceived odds that similar molecules — including Bristol Myers’ milvexian — can succeed in at least some indications, which translated into a multi‑percent pop in BMY stock. (investors.com)

A quick look at the players and timeline

• Bayer: announced positive topline results from OCEANIC‑STROKE on November 23, 2025, and said detailed results will be presented at an upcoming scientific congress. The company plans to engage regulators about potential marketing applications. (bayer.com)
• Bristol Myers Squibb: developing milvexian, another oral Factor XIa inhibitor. Milvexian had an earlier setback when an acute coronary syndrome (ACS) trial was halted for likely futility, but analysts now see greater odds for success in secondary stroke prevention after Bayer’s news. Bristol Myers expects key readouts for atrial fibrillation and stroke indications in 2026 (stroke) and late 2026 (AF study topline timing noted by analysts). (investors.com)
• Regeneron and other firms: also saw small moves after Bayer’s announcement, reflecting industry‑wide implications for the FXIa inhibitor class. (investors.com)

Why investors care beyond a single trial result

• The unmet-need math is compelling: recurrent stroke risk remains high, and current oral anticoagulants (like Factor Xa inhibitors) come with bleeding tradeoffs that limit use in some patients. A therapy that meaningfully lowers ischemic stroke risk without increasing major bleeding could shift practice and command large market share. (bayer.com)
• Drug development in cardiovascular and stroke indications often translates into multibillion‑dollar peak sales if regulators and clinicians accept the benefit/risk profile — which is why analysts quickly remapped revenue forecasts after Bayer’s topline. (investors.com)
• But “class validation” isn’t a guarantee. Molecules differ in pharmacology, trial designs matter, and regulatory hurdles remain. A positive headline helps, but each candidate must prove itself on its own data.

What to watch next

• Full data release: details on event rates, absolute risk reduction, subgroup analyses, and bleeding definitions (ISTH major bleeding vs. other metrics) will determine how convincing the result really is. Bayer said full results will be presented at a scientific meeting. (bayer.com)
• Bristol Myers’ milvexian readouts: timing and endpoints for milvexian’s stroke and atrial fibrillation trials — and whether milvexian reproduces asundexian’s safety/efficacy balance. Analysts have already increased probability estimates for some milvexian indications; the market will watch for Bristol’s own numbers. (investors.com)
• Regulatory feedback: Bayer plans to engage health authorities about applications; regulators’ responses (and any requests for additional data) will shape the approval timeline and commercial prospects. (reuters.com)

Market and scientific nuance

• Proof‑of‑concept at large scale: OCEANIC‑STROKE reportedly enrolled over 12,000 patients — a sizable dataset that, if robust, gives the result weight beyond small, early trials. Large phase III success can be a genuine inflection point. (bayer.com)
• Not all indications are equal: Bayer’s win was in secondary stroke prevention; earlier failures (e.g., atrial fibrillation) remind us that efficacy can vary by disease context. Analysts noted Bayer’s prior AF setback and cautioned extrapolating to every indication. (reuters.com)
• Competitive landscape: multiple companies are racing to develop FXIa inhibitors. A first approval for the class would change competitive dynamics rapidly, but differentiation (oral dosing, safety, efficacy in key subgroups) will matter for long‑term market share.

A few bite‑sized takeaways

• Bayer’s OCEANIC‑STROKE topline appears to validate the therapeutic potential of FXIa inhibition for secondary stroke prevention. (bayer.com)
• That validation lifted investor sentiment for peers, including Bristol Myers, which benefits from a stronger belief in milvexian’s prospects despite prior setbacks. (investors.com)
• Full data, regulatory reviews, and individual trial differences still determine winners — a class win is helpful, but not decisive.

My take

This is what makes biotech markets both thrilling and maddening: a single credible late‑stage readout can switch narratives overnight. Bayer’s result is an important proof‑point for Factor XIa inhibition and opens the door for rivals — but each program still needs to clear its own clinical and regulatory hurdles. For long‑term investors or clinicians, the sensible posture is curiosity plus scrutiny: welcome the class validation, then ask for the full data and watch how each molecule performs in its own trials.

Sources

• Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC‑STROKE Study in Secondary Stroke Prevention — Bayer.
  https://www.bayer.com/en/us/news-stories/oceanic-stroke. (bayer.com)

• Bayer reports positive results for blood thinner after 2023 setback — Reuters, Nov 23, 2025.
  https://www.reuters.com/sustainability/boards-policy-regulation/bayer-reports-positive-results-blood-thinner-after-2023-setback-2025-11-23/. (reuters.com)

• Bristol Myers Pops On A 'Surprisingly Positive' Update From Key Rival Bayer — Investor’s Business Daily, Nov 24, 2025.
  https://www.investors.com/news/technology/bristol-myers-squibb-bayer-blood-thinner-stroke-prevention/. (investors.com)

• Bayer shares up more than 8% on revived fortunes for blood thinner — Financial Times, Nov 24, 2025.
  https://www.ft.com/content/ff8c225a-90fe-4c0e-a2cf-83877ed9a824. (ft.com)